Lessons from building a full-risk specialty care model: how Atlas Oncology Partners achieved contract precision at speed and scale
Full-risk specialty care models are among the most complex—and highest-stakes—arrangements in value-based care. For organizations taking on full risk, the margin for error is razor-thin: small differences in inclusion/exclusion criteria, lookback periods, or qualifying encounters can compound into millions of dollars across multi-year contracts.
Atlas Oncology Partners knows this firsthand. Negotiating with multiple payers, it became clear that an isolated static actuarial model was not sufficient. They needed the ability to test, compare, and validate unique payer terms dynamically, with confidence in every assumption.
To learn from their journey, we’ll be joined by Dr. David Johnson, Co-Founder & Chief Physician Executive of Atlas Oncology Partners, alongside Dr. Robin Clarke, CEO of Ursa Health.
We’ll cover:
Atlas’ care model and what they learned early on in bringing it to payers
How partnering with Ursa transformed how they model and manage risk, from early negotiations through program operations to reconciliation
Why Ursa starts with data as the foundation and partners with organizations at all levels of sophistication
Real contract modeling to illustrate the financial and population impacts of small parameter changes
What it’s like to negotiate backed by transparent, reproducible data that payers trust
Whether you’re pre-contract or looking to scale, this session is designed for clinical leaders and senior operators navigating specialty value-based care.
This event is sponsored by Ursa Health.